ADMA Biologics, Inc.ADMANASDAQ
Loading
SG&A Expense Growth TrendStable
Percentile Rank36
3Y CAGR+1.9%
5Y CAGR-7.8%
Studio
Year-over-Year Change

Year-over-year SG&A expense growth

3Y CAGR
+1.9%/yr
vs -2.2%/yr prior
5Y CAGR
-7.8%/yr
Recent acceleration
Acceleration
+4.1pp
Accelerating
Percentile
P36
Within normal range
vs 5Y Ago
0.7x
Contraction
Streak
1 yr
Consecutive declineStable
PeriodValue
202523.55%
202425.59%
202312.51%
202222.29%
202122.39%
202035.28%
201915.14%
201824.37%
2017112.99%
201625.92%